rajasekharkakarla
☆    

India,
2019-09-20 08:35
(2118 d 13:52 ago)

Posting: # 20628
Views: 2,351
 

 Reference replicated designs [Regulatives / Guidelines]

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,693 registered users;
56 visitors (0 registered, 56 guests [including 14 identified bots]).
Forum time: 22:27 CEST (Europe/Vienna)

Anyone who conducts an argument by appealing to authority
is not using his intelligence;
he is just using his memory.    Leonardo da Vinci

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5